131 related articles for article (PubMed ID: 32017945)
1. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
[TBL] [Abstract][Full Text] [Related]
2. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
3. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
Aman M; Ohishi Y; Imamura H; Shinozaki T; Yasutake N; Kato K; Oda Y
Hum Pathol; 2017 Jun; 64():156-163. PubMed ID: 28438620
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3 expression in primary and recurrent ovarian carcinomas.
Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G
Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
6. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
8. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
9. Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases.
He H; Fang W; Liu X; Weiss LM; Chu PG
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):40-6. PubMed ID: 18813128
[TBL] [Abstract][Full Text] [Related]
10. Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening.
Rodriguez M; Kang EY; Farrington K; Cook LS; Le ND; Karnezis AN; Lee CH; Nelson GS; Terzic T; Lee S; Köbel M
Am J Surg Pathol; 2021 Nov; 45(11):1452-1463. PubMed ID: 34534137
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
12. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth.
Luo C; Shibata K; Suzuki S; Kajiyama H; Senga T; Koya Y; Daimon M; Yamashita M; Kikkawa F
Oncol Rep; 2014 Sep; 32(3):913-21. PubMed ID: 24992906
[TBL] [Abstract][Full Text] [Related]
13. Expression of glypican 3 in placental site trophoblastic tumor.
Ou-Yang RJ; Hui P; Yang XJ; Zynger DL
Diagn Pathol; 2010 Sep; 5():64. PubMed ID: 20868507
[TBL] [Abstract][Full Text] [Related]
14. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
15. [Cancer peptide vaccine targeted glypican-3 antigen].
Nakatsura T
Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.
Suzuki S; Sakata J; Utsumi F; Sekiya R; Kajiyama H; Shibata K; Kikkawa F; Nakatsura T
Oncoimmunology; 2016; 5(11):e1238542. PubMed ID: 27999758
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.
Gailey MP; Bellizzi AM
Am J Clin Pathol; 2013 Dec; 140(6):872-80. PubMed ID: 24225756
[TBL] [Abstract][Full Text] [Related]
19. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.
Pan C; Wang X; Chen W; Tao C; Xu X; Jin L; Chen Y; Zhu L; Zhou L; Pan Z
Med Oncol; 2015 Jan; 32(1):359. PubMed ID: 25432695
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 Differentiates Intraductal Carcinoma and Paget's Disease from Other Types of Breast Cancer.
Alshammari FO; Satari AO; Aljabali AS; Al-Mahdy YS; Alabdallat YJ; Al-Sarayra YM; Alkhojah MA; Alwardat ARM; Haddad M; Al-Sarayreh SA; Al-Saraireh YM
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676710
[No Abstract] [Full Text] [Related]
[Next] [New Search]
